Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Recurrent Genital Herpes Clinical Trial

Official title:
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Status Completed

Clinical Trial Summary

This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes.

This study is not recruiting patients in the United States.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00171990
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	January 2003
Completion date	February 2006

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT04714060` - UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals	Phase 2
	Not yet recruiting	`NCT04979975` - Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes	Phase 2